Ken Griffin’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-19,247
| Closed | -$37.5K | – | 15876 |
|
|
2023
Q4 | $37.5K | Buy |
19,247
+6,422
| +50% | +$12.9K | ﹤0.01% | 12066 |
|
|
2023
Q3 | $30.9K | Buy |
+12,825
| New | +$31.6K | ﹤0.01% | 12252 |
|
|
2022
Q2 | – | Sell |
-13
| Closed | -$5K | – | 14621 |
|
|
2022
Q1 | $5K | Sell |
13
-72
| -85% | -$46K | ﹤0.01% | 13431 |
|
|
2021
Q4 | $84K | Buy |
85
+69
| +431% | +$97.3K | ﹤0.01% | 12900 |
|
|
2021
Q3 | $32K | Sell |
16
-49
| -75% | -$111K | ﹤0.01% | 13557 |
|
|
2021
Q2 | $174K | Sell |
65
-33
| -34% | -$109K | ﹤0.01% | 12328 |
|
|
2021
Q1 | $408K | Buy |
98
+49
| +100% | +$265K | ﹤0.01% | 10133 |
|
|
2020
Q4 | $280K | Buy |
49
+13
| +36% | +$76.5K | ﹤0.01% | 9190 |
|
|
2020
Q3 | $219K | Sell |
36
-12
| -25% | -$68.8K | ﹤0.01% | 8669 |
|
|
2020
Q2 | $268K | Buy |
48
+15
| +45% | +$77.9K | ﹤0.01% | 8093 |
|
|
2020
Q1 | $123K | Buy |
+33
| New | +$189K | ﹤0.01% | 8472 |
|
|
2018
Q4 | – | Sell |
-32
| Closed | -$24K | – | 9966 |
|
|
2018
Q3 | $24K | Buy |
+32
| New | +$23.4K | ﹤0.01% | 8982 |
|
|
2016
Q1 | – | Sell |
-5
| Closed | -$106K | – | 8287 |
|
|
2015
Q4 | $106K | Buy |
+5
| New | +$79.1K | ﹤0.01% | 6618 |
|
Other funds holding AGRX
Ken Griffin's AGRX Position: Q1 2024 in Review
Ken Griffin sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 19,247 shares — an estimated $37.5K sold.
Ken Griffin first reported a position in AGRX in Q4 2015 and held it in 13 quarters. The position peaked at $408K in Q1 2021. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Ken Griffin reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Ken Griffin sold 19,247 Agile Therapeutics shares in Q1 2024, an estimated $37.5K.
- Ken Griffin first reported a position in Agile Therapeutics in Q4 2015 and held it in 13 quarters.
- Ken Griffin's Agile Therapeutics position peaked at $408K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.